Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRX215 study after liver resection for colorectal liver metastases
MOH_2026-04-19_015774Phase 2Recruiting
- Sponsor
- HepaRegeniX GmbH
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of darizmetinib in colorectal cancer (CRC) (3 arms), sponsored by HepaRegeniX GmbH. Started Mar 2026; status: recruiting.
02
Drugs
darizmetinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on MOH_2026-04-19_015774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-04-19_015774.